HUTCHMED (NASDAQ:HCM) Shares Gap Down – Should You Sell?

HUTCHMED (China) Limited (NASDAQ:HCM) shares gapped down prior to trading on Monday . The stock had previously closed at $15.69, but opened at $15.03. HUTCHMED shares last traded at $15.05, with a volume of 17,368 shares changing hands.

HUTCHMED Stock Down 1.3 %

The stock has a fifty day moving average price of $14.65 and a 200-day moving average price of $16.53. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.

Hedge Funds Weigh In On HUTCHMED

Hedge funds have recently modified their holdings of the stock. Jane Street Group LLC increased its stake in shares of HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after acquiring an additional 49,366 shares during the last quarter. State Street Corp increased its stake in shares of HUTCHMED by 0.9% in the third quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after acquiring an additional 3,078 shares during the last quarter. ABC Arbitrage SA acquired a new position in shares of HUTCHMED in the fourth quarter worth $500,000. XY Capital Ltd acquired a new position in shares of HUTCHMED in the fourth quarter worth $673,000. Finally, Crossmark Global Holdings Inc. increased its stake in shares of HUTCHMED by 10.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock worth $268,000 after acquiring an additional 1,799 shares during the last quarter. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.